NGEN
NervGen Pharma Corp.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$293.78M
P/E Ratio
—
EPS
$-0.45
Beta
0.99
52W High
$6.30
52W Low
$1.50
50-Day MA
$4.02
200-Day MA
$3.55
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NervGen Pharma Corp.
Nanogen Inc (NGEN) is a cutting-edge biotechnology company dedicated to advancing molecular diagnostic technologies aimed at improving patient outcomes through innovative genomic analysis solutions. The firm specializes in the development and commercialization of products tailored to complex disease targets, utilizing its proprietary platforms to deliver precise and timely diagnostics. With a robust focus on research and development, Nanogen is poised to expand its portfolio and drive growth in the dynamic diagnostic market, aligning with the industry's shift toward personalized medicine and the increasing demand for sophisticated diagnostic tools.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-25.02M |
| Operating Margin | 0.00% |
| Return on Equity | -1458.00% |
| Return on Assets | -73.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.03 |
| Price-to-Book | 116.55 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -5.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $80.93M |
| Float | $68.91M |
| % Insiders | 20.74% |
| % Institutions | 0.51% |
Historical Volatility
HV 10-Day
35.01%
HV 20-Day
53.40%
HV 30-Day
65.44%
HV 60-Day
66.08%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($10.39 target)
3
Strong Buy1
BuyMore HEALTHCARE Stocks
Data last updated: 5/2/2026